৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Products
Payment
Delivery
Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Pharmacology
Linagliptin: DPP-4 inhibitor. Increases active incretin hormones (GLP-1, GIP), stimulating insulin release in a glucose-dependent manner and reducing glucagon secretion. This lowers hepatic glucose output and improves glycemic control.
Empagliflozin: SGLT2 inhibitor. Reduces renal glucose reabsorption, lowers renal threshold for glucose, and increases urinary glucose excretion.
Dosage & Administration
Recommended dose: 10 mg Empagliflozin + 5 mg Linagliptin once daily, morning, with or without food.
Dose may be increased to 25 mg Empagliflozin + 5 mg Linagliptin once daily.
Assess renal function before initiation. Do not start if eGFR <45 ml/min/1.73 m². Discontinue if eGFR falls below 45 ml/min/1.73 m².
Interactions
Diuretics: Increased urine volume and frequency → risk of volume depletion.
Insulin or secretagogues: Increased risk of hypoglycemia.
P-gp/CYP3A4 inducers (e.g., Rifampin): May reduce Linagliptin efficacy.
SGLT2 inhibitors: Cause positive urine glucose test.
1,5-AG assay: Results unreliable in patients on SGLT2 inhibitors.
Contraindications
Severe renal impairment, end-stage renal disease, or dialysis.
History of hypersensitivity to Linagliptin (e.g., anaphylaxis, angioedema, urticaria, bronchial hyperreactivity).
History of serious hypersensitivity to Empagliflozin.
Side Effects
Pancreatitis, ketoacidosis, volume depletion, urinary tract infections (urosepsis, pyelonephritis), hypoglycemia (with insulin/secretagogues), necrotizing fasciitis of perineum (Fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, severe arthralgia, bullous pemphigoid, heart failure.
Pregnancy & Lactation
Not recommended during 2nd and 3rd trimesters.
Limited data in pregnancy; risks associated with poorly controlled diabetes.
Use caution in lactation.
Precautions & Warnings
Monitor for pancreatitis, ketoacidosis, hypotension, acute kidney injury, urinary tract infections, hypoglycemia, genital infections, hypersensitivity.
Reports of ketoacidosis and rare Fournier’s gangrene with SGLT2 inhibitors.
Association between DPP-4 inhibitors and heart failure observed in trials.
Overdose Effects
Contact Poison Control. Supportive measures: remove unabsorbed material, clinical monitoring, supportive treatment.
Hemodialysis unlikely to remove Linagliptin; Empagliflozin removal not studied.






N/A
N/A





